For the treatment of rheumatoid arthritis, a large inventory of 5 types of guideline-recommended drugs

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease that occurs mostly in middle-aged and elderly women, with a global incidence of about 1%

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease that occurs mostly in middle-aged and elderly women, with a global incidence of about 1%

(Image source: Photo Network)

(Image source: Photo Network)

1 Disease-modifying antirheumatic drugs (DMARDs)

1 Disease-modifying antirheumatic drugs 1 Disease-modifying antirheumatic drugs (DMARDs) These drugs slow the progression of rheumatoid arthritis and protect joints and other tissues protected from permanent damage .

Nonsteroidal anti-inflammatory drugs Nonsteroidal anti-inflammatory drugs (NSAIDs) (Nonsteroidal anti-inflammatory drugs, NSAIDs)

NSAIDs are antipyretic, analgesic, and anti-inflammatory drugs that do not contain steroids, but have limited effects on disease control, and should be taken together with DMARDs

NSAIDs are antipyretic, analgesic, and anti-inflammatory drugs that do not contain steroids, but have limited effects on disease control, and should be taken together with DMARDs

Commonly used NSAIDs include ibuprofen and celecoxib capsules (Celebrex)

3

Glucocorticoids

glucocorticoid glucocorticoid

Glucocorticoids, such as prednisone, have immune-modulating and anti-inflammatory properties, reduce inflammation and pain, and slow joint damage

Glucocorticoids, such as prednisone, have immune-modulating and anti-inflammatory properties, reduce inflammation and pain, and slow joint damage

 

 4.

 

5 Botanicals Botanicals

Such as tripterygium wilfordii polyglycosides, total glucosides of paeony, sinomenine, etc.

Such as tripterygium wilfordii polyglycosides, total glucosides of paeony, sinomenine, etc.

The therapeutic drug market for RA has great potential and has achieved rapid development in the past few decades, especially the biologics DMARDs

It is believed that with the emergence of more and more new biological agents and the completion of more and more relevant clinical studies, medical personnel in the rheumatology field will be able to make better use of this weapon to make RA treatment more standardized and patients' prognosis better

references:

references:

[1] Shiman.

[1] Shiman.

[2] Wang Jing, Zhao Qingjie, Zhuo Xiaobin, et al.

[3] Rheumatology Branch of Chinese Medical Association.
2018 Guidelines for Diagnosis and Treatment of Rheumatoid Arthritis in China [J].
Chinese Journal of Internal Medicine, 2018, 57(4): 242-251.

[4] Fang Linkai, Huang Caihong, Xie Ya, et al.
Practice guidelines for patients with rheumatoid arthritis [J].
Chinese Journal of Internal Medicine, 2020, 59(10): 772-780.

[4] Fang Linkai, Huang Caihong, Xie Ya, et al.
Practice guidelines for patients with rheumatoid arthritis [J].
Chinese Journal of Internal Medicine, 2020, 59(10): 772-780.

[5] Liu Xia, Wang Guochun.
Advances in the application of biological agents in rheumatoid arthritis [J].
Journal of Clinical Internal Medicine, 2013, 30(10): 656-658.

[5] Liu Xia, Wang Guochun.
Advances in the application of biological agents in rheumatoid arthritis [J].
Journal of Clinical Internal Medicine, 2013, 30(10): 656-658.


Leave a message here